| Name | Title | Contact Details |
|---|
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Vetagro is a company that specializes in feed additive development and production for the animal feed industry. They focus on developing targeted solutions through scientific research, technological development, innovative formulation, and a focus on q...
Roche is a multinational healthcare company that creates innovative medicines and diagnostic tests to prevent, diagnose, and treat diseases. The company is committed to improving lives and making a sustainable contribution to society.
Pharma Test-Americas is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.